Phase II Study with 5-Fluorouracil and Ginkgo biloba Extract (GBE 761 ONC) in Patients with Pancreatic Cancer
暂无分享,去创建一个
C. Unger | S. Köhler | K. Mross | B. Hauns | B. Häring | P. Robben-Bathe
[1] S. Ha,et al. Enhancement of radiation effect by Ginkgo biloba extract in C3H mouse fibrosarcoma. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[2] G. Milano,et al. Critical factors for optimizing the 5-fluorouracil-folinic acid association in cancer chemotherapy. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] A. Harris,et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. , 1996, British Journal of Cancer.
[4] T. Fleming,et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] O. Eber,et al. Dose-dependent hemorheological effects and microcirculatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761 , 1995 .
[6] P. Fuchs,et al. Myricetin and quercetin, the flavonoid constituents ofGinkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca2+-loaded brain neurons , 1994, Brain Research.
[7] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[8] H. Pinedo,et al. Fluorouracil: biochemistry and pharmacology. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] L. Edler,et al. Remission in Phase-II- und Phase-III-Studien: Kriterien und Voraussetzungen , 1987 .
[10] F. Mícek. [Cancer of the pancreas]. , 1965, Bratislavske lekarske listy.